Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ANVS NASDAQ:CORT NASDAQ:JAZZ NASDAQ:RPRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANVSAnnovis Bio$1.70-22.7%$2.37$1.11▼$10.54$42.87M1.63645,492 shs7.79 million shsCORTCorcept Therapeutics$73.96-16.3%$75.57$42.01▼$117.33$9.31B0.46955,065 shs2.28 million shsJAZZJazz Pharmaceuticals$135.43-2.0%$125.87$95.49▼$148.06$8.38B0.28746,129 shs487,763 shsRPRXRoyalty Pharma$36.01-0.4%$36.18$24.05▼$38.00$21.08B0.65.07 million shs2.03 million shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANVSAnnovis Bio-23.08%-23.25%-26.09%-37.50%-78.91%CORTCorcept Therapeutics-16.30%-16.10%+3.27%+2.89%+60.99%JAZZJazz Pharmaceuticals-1.97%-2.90%+6.72%+22.82%+26.19%RPRXRoyalty Pharma-0.36%-0.17%-0.47%+0.47%+30.57%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANVSAnnovis Bio$1.70-22.7%$2.37$1.11▼$10.54$42.87M1.63645,492 shs7.79 million shsCORTCorcept Therapeutics$73.96-16.3%$75.57$42.01▼$117.33$9.31B0.46955,065 shs2.28 million shsJAZZJazz Pharmaceuticals$135.43-2.0%$125.87$95.49▼$148.06$8.38B0.28746,129 shs487,763 shsRPRXRoyalty Pharma$36.01-0.4%$36.18$24.05▼$38.00$21.08B0.65.07 million shs2.03 million shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANVSAnnovis Bio-23.08%-23.25%-26.09%-37.50%-78.91%CORTCorcept Therapeutics-16.30%-16.10%+3.27%+2.89%+60.99%JAZZJazz Pharmaceuticals-1.97%-2.90%+6.72%+22.82%+26.19%RPRXRoyalty Pharma-0.36%-0.17%-0.47%+0.47%+30.57%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANVSAnnovis Bio 2.33Hold$17.33919.61% UpsideCORTCorcept Therapeutics 2.57Moderate Buy$135.2582.87% UpsideJAZZJazz Pharmaceuticals 2.76Moderate Buy$178.9332.12% UpsideRPRXRoyalty Pharma 3.20Buy$46.0027.74% UpsideCurrent Analyst Ratings BreakdownLatest CORT, ANVS, RPRX, and JAZZ Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/10/2025RPRXRoyalty PharmaMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$55.00 ➝ $54.0010/10/2025CORTCorcept TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$145.0010/8/2025ANVSAnnovis BioWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025CORTCorcept TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)10/8/2025JAZZJazz PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)10/8/2025RPRXRoyalty PharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C+) ➝ Buy (B-)10/1/2025CORTCorcept TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell9/30/2025RPRXRoyalty PharmaThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$42.009/30/2025ANVSAnnovis BioCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$17.009/30/2025RPRXRoyalty PharmaThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$42.009/27/2025ANVSAnnovis BioWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 10/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANVSAnnovis BioN/AN/AN/AN/A$0.67 per shareN/ACORTCorcept Therapeutics$675.04M11.54$1.04 per share71.14$6.49 per share11.40JAZZJazz Pharmaceuticals$4.07B2.02$29.76 per share4.55$67.72 per share2.00RPRXRoyalty Pharma$2.26B9.28$4.18 per share8.61$17.56 per share2.05Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANVSAnnovis Bio-$24.59M-$2.04N/AN/AN/AN/A-206.01%-158.26%11/14/2025 (Estimated)CORTCorcept Therapeutics$141.21M$1.1365.4539.98N/A18.51%20.10%16.20%10/29/2025 (Estimated)JAZZJazz Pharmaceuticals$560.12M-$6.73N/A7.248.48-9.91%5.02%1.73%11/5/2025 (Estimated)RPRXRoyalty Pharma$858.98M$1.7320.827.412.2844.23%25.54%14.11%11/5/2025 (Estimated)Latest CORT, ANVS, RPRX, and JAZZ EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/5/2025Q3 2025JAZZJazz Pharmaceuticals$5.87N/AN/AN/A$1.11 billionN/A11/5/2025Q3 2025RPRXRoyalty Pharma$1.11N/AN/AN/A$765.01 millionN/A10/29/2025Q3 2025CORTCorcept Therapeutics$0.22N/AN/AN/A$223.78 millionN/A8/12/2025Q2 2025ANVSAnnovis Bio-$0.36-$0.32+$0.04-$0.32N/AN/A8/6/2025Q2 2025RPRXRoyalty Pharma$1.10$1.14+$0.04$0.05$750.06 million$578.67 million8/5/2025Q2 2025JAZZJazz Pharmaceuticals-$5.61-$8.25-$2.64-$11.74$1.05 billion$1.05 billion7/31/2025Q2 2025CORTCorcept Therapeutics$0.23$0.29+$0.06$0.29$199.40 million$194.43 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANVSAnnovis BioN/AN/AN/AN/AN/ACORTCorcept TherapeuticsN/AN/AN/AN/AN/AJAZZJazz PharmaceuticalsN/AN/AN/AN/AN/ARPRXRoyalty Pharma$0.882.44%N/A50.87%5 YearsLatest CORT, ANVS, RPRX, and JAZZ DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date7/18/2025RPRXRoyalty Pharmaquarterly$0.222.48%8/15/20258/15/20259/10/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANVSAnnovis BioN/A7.657.65CORTCorcept TherapeuticsN/A3.062.98JAZZJazz Pharmaceuticals1.171.621.37RPRXRoyalty Pharma0.741.261.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANVSAnnovis Bio15.83%CORTCorcept Therapeutics93.61%JAZZJazz Pharmaceuticals89.14%RPRXRoyalty Pharma54.35%Insider OwnershipCompanyInsider OwnershipANVSAnnovis Bio20.80%CORTCorcept Therapeutics20.80%JAZZJazz Pharmaceuticals4.30%RPRXRoyalty Pharma18.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANVSAnnovis Bio319.49 million15.43 millionOptionableCORTCorcept Therapeutics300105.37 million83.46 millionOptionableJAZZJazz Pharmaceuticals2,80060.66 million58.05 millionOptionableRPRXRoyalty Pharma80583.17 million472.95 millionOptionableCORT, ANVS, RPRX, and JAZZ HeadlinesRecent News About These CompaniesKLP Kapitalforvaltning AS Increases Position in Royalty Pharma PLC $RPRXOctober 11 at 3:45 AM | marketbeat.comBelpointe Asset Management LLC Purchases New Position in Royalty Pharma PLC $RPRXOctober 11 at 3:35 AM | marketbeat.comMorgan Stanley Maintains Royalty Pharma (RPRX) Overweight RecommendationOctober 11 at 3:23 AM | msn.comRoyalty Pharma price target lowered to $54 from $55 at Morgan StanleyOctober 10 at 12:20 PM | msn.comRoyalty Pharma to Announce Third Quarter 2025 Financial Results on November 5, 2025October 9 at 4:15 PM | globenewswire.comRoyalty Pharma (NASDAQ:RPRX) Raised to Buy (B-) at Weiss RatingsOctober 9 at 4:58 AM | marketbeat.comWill Royalty Pharma (RPRX) Beat Estimates Again in Its Next Earnings Report?October 8 at 1:11 PM | zacks.comThese 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your RadarOctober 6, 2025 | zacks.comRoyalty Pharma PLC $RPRX Position Increased by Robeco Institutional Asset Management B.V.October 4, 2025 | marketbeat.comRoyalty Pharma PLC (NASDAQ:RPRX) Given Average Rating of "Buy" by AnalystsOctober 3, 2025 | marketbeat.comRoyalty Pharma (NASDAQ:RPRX) Earns Buy Rating from Analysts at The Goldman Sachs GroupOctober 3, 2025 | americanbankingnews.comRoyalty Pharma (NASDAQ:RPRX) Upgraded by The Goldman Sachs Group to "Strong-Buy" RatingOctober 2, 2025 | marketbeat.comGoldman Sachs Initiates Coverage of Royalty Pharma (RPRX) with Buy RecommendationOctober 1, 2025 | msn.comRoyalty Pharma initiated with a Buy at Goldman SachsSeptember 30, 2025 | msn.comRoyalty Pharma appoints Ted Love as lead independent directorSeptember 29, 2025 | msn.comRoyalty Pharma Appoints Dr. Ted W. Love As Lead Independent DirectorSeptember 29, 2025 | globenewswire.comOverbrook Management Corp Trims Position in Royalty Pharma PLC $RPRXSeptember 29, 2025 | marketbeat.comAssessing Royalty Pharma (RPRX): Is the Recent Outperformance Reflected in Its Current Valuation?September 27, 2025 | finance.yahoo.comBank Pictet & Cie Europe AG Cuts Holdings in Royalty Pharma PLC $RPRXSeptember 27, 2025 | marketbeat.comRuffer LLP Makes New $6.41 Million Investment in Royalty Pharma PLC $RPRXSeptember 25, 2025 | marketbeat.comRoyalty Pharma plc (RPRX) Completes $2B Senior Notes Offering, Strengthens Capital for GrowthSeptember 24, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCORT, ANVS, RPRX, and JAZZ Company DescriptionsAnnovis Bio NYSE:ANVS$1.70 -0.50 (-22.73%) Closing price 10/10/2025 03:59 PM EasternExtended Trading$1.69 -0.01 (-0.59%) As of 10/10/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.Corcept Therapeutics NASDAQ:CORT$73.96 -14.40 (-16.30%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$75.47 +1.52 (+2.05%) As of 10/10/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.Jazz Pharmaceuticals NASDAQ:JAZZ$135.43 -2.72 (-1.97%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$134.56 -0.88 (-0.65%) As of 10/10/2025 06:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.Royalty Pharma NASDAQ:RPRX$36.01 -0.13 (-0.36%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$35.61 -0.40 (-1.12%) As of 10/10/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom Gets Second $420 Target as CPO Win Boosts Outlook Why Amazon’s Prime Day May Be the Catalyst for a Year-End Rally PepsiCo’s Deep Discount Will Soon Evaporate: Buy It While You Can Bargain Alert: DraftKings Is the Most Oversold It’s Ever Been Constellation Brands: Buffett’s $2.2B Bet May Have Hit Bottom How Gamers Are Powering Microsoft’s Next Wave of Growth AI Meets Nuclear: Palantir’s Role in Energy Expansion Buy the Dip? Zillow’s Profit Comeback Meets Market Pressure Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
